The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model

mBio

Volumn 1, Issue 3, 2010, Pages

  Drusano, G L ^a   Sgambati, Nicole ^a   Eichas, Adam ^a   Brown, David L ^a   Kulawy, Robert ^a   Louie, Arnold ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; ISONIAZID; METRONIDAZOLE; MOXIFLOXACIN; RIFAMPICIN;

ANAEROBIC GROWTH; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; HOLLOW FIBER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 79952126850     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00139-10     Document Type: Article

References (17)

1. Selkon, J. B., S. Devadatta, D. A. Mitchison, A. S. Narayana, C. N. Nair, and K. Ramachandran. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull. World Health Organ. 31:273-294.
2. Almeida, D., E. Nuermberger, R. Tasneen, I. Rosenthal, S. Tyagi, K. Williams, C. Peloquin, and J. Grosset. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 53:4178-4184.
3. Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36: 548-551.
4. Dickinson, J. M., V. R. Aber, and D. A. Mitchison. 1977. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 116:637-635.
5. Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
6. Garton, N. J., S. J. Waddell, A. L. Sherratt, S. M. Lee, R. J. Smith, C. Senner, J. Hinds, K. Rajakumar, R. A. Adegbola, G. S. Besra, P. D. Butcher, and M. R. Barer. 2008. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 5:e75.
7. Desjardin, L. E., L. G. Hayes, C. D. Sohaskey, L. G. Wayne, and K. D. Eisenach. 2001. Microaerophilic induction of the alpha-crystallin chaperone protein homologue (hspX) mRNA of Mycobacterium tuberculosis. J. Bacteriol. 183:5311-5316.
8. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
9. Wayne, L. G., and L. G. Hayes. 1998. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuber. Lung Dis. 79: 127-132.
10. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
11. Drusano, G. L., W. Liu, C. Fregeau, R. Kulawy, and A. Louie. 2009. Differing effect of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance on wild-type Pseudomonas aeruginosa PA01 and its isogenic MexAB efflux pumpoverexpressed mutant. Antimicrob. Agents Chemother. 53:2266-2273.
12. Gefen, O., C. Gabay, M. Municoglu, G. Engel, and N. Q. Balaban. 2008. Single cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. Proc. Natl. Acad. Sci. U. S. A. 105: 6145-6149.
13. Dorman, S. E., J. L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C. M. Heilig, J. Bernardo, S. Choudhri, J. H. Grosset, E. Guy, P. Guyadeen, M. C. Leus, G. Maltas, D. Menzies, E. L. Nuermberger, M. Villarino, A. Vernon, R. E. Chaisson, and the Tuberculosis Trials Consortium. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
14. Conde, M. B., A. Efron, C. Loredo, G. R. De Souza, N. P. Graça, M. C. Cezar, M. Ram, M. A. Chaudhary, W. R. Bishai, A. L. Kritski, and R. E. Chaisson. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
15. Yuan, Y., D. D. Crane, and C. E. Barry. 1996. Stationary phaseassociated protein expression in Mycobacterium tuberculosis: function of the mycobacterial α-crystallin homolog. J. Bacteriol. 178:4484-4492.
16. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
17. Clincial and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.